Abstract
Intravenous (IV) antibiotic therapy for pulmonary exacerbations (PE) has been shown to improve pulmonary functioning for patients with cystic fibrosis (CF); however, little is known about its effects on pediatric health-related quality of life (HRQOL). This prospective study assessed the impact of IV treatment of a PE on generic and CF-specific HRQOL for children and adolescents with CF. Participants included 52 children and adolescents with CF experiencing a PE (M age = 13.6 years; 54% males; \( M_{{{\text{FEV}}_{1\% } }} \) predicted = 58.8%). HRQOL, pulmonary functioning, and body mass index were assessed before and after IV antibiotic treatment. Results of this prospective, observational study indicated significant improvements on CFQ-R Respiratory (M change score = 11.7; 95% CI = 6.3–17.1; p < .0001) and Weight (M change score = 15.9; 95% CI = 7.9–23.8; p < .0001) scales. The CF-specific measure was more sensitive to changes in HRQOL than the generic instrument. These data suggest that CF-specific HRQOL improves with treatment for a PE with IV antibiotics. The noted statistically and clinically significant changes in the CFQ-respiratory scale indicate that the measure may be beneficial to pulmonary health care teams.
Similar content being viewed by others
References
Abbott, J., Webb, K., & Dodd, M. (1997). Quality of life in cystic fibrosis. Journal of the Royal Society of Medicine, 90, 37–42.
Beaton, D. E., Boers, M., & Wells, G. A. (2002). Many faces of the minimal clinically important difference (MCID): A literature review and directions for future research. Current Opinions in Rheumatology, 14, 109–114.
Bradley, J., McAlister, O., & Elborn, S. (2001). Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. European Respiratory Journal, 17, 712–715.
Britto, M. T., Kotagal, U. R., Hornung, R. W., Atherton, H. D., Tsevat, J., & Wilmott, R. W. (2002). Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest, 121, 64–72.
Cerny, F. J., Cropp, G. J., & Bye, M. R. (1984). Hospital therapy improves exercise tolerance and lung function in cystic fibrosis. American Journal of Diseases of Children, 138, 261–265.
Clayton, R. G., Sr., Diaz, C. E., Bashir, N. S., Panitch, H. B., Schidlow, D. V., & Allen, J. L. (1998). Pulmonary function in hospitalized infants and toddlers with cystic fibrosis. Journal of Pediatrics, 132, 405–408.
Cystic Fibrosis Foundation. (2004). Patient registry 2003 annual report. Bethesda, Maryland.
Cystic Fibrosis Foundation. (2007). About cystic fibrosis. Retrieved June 5, 2007, from www.cff.org/AboutCF/.
Dakin, C., Henry, R. L., Field, P., & Morton, J. (2001). Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatric Pulmonology, 31, 436–442.
Esmond, G., Butler, M., & McCormack, A. M. (2006). Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. Journal of Clinical Nursing, 15, 52–60.
Goss, C. H., & Burns, J. L. (2007). Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax, 62, 360–367.
Goss, C. H., & Quittner, A. L. (2007). Patient-reported outcomes in cystic fibrosis. Proceedings of the American Thoracic Society, 4, 378–386.
Guyatt, G. H. (2000). Making sense of quality-of-life data. Medical Care, 38, 175–179.
Hankinson, J. L., Odencrantz, J. R., & Fedan, K. B. (1999). Spirometric reference values from a sample of the general U.S. population. American Journal of Respiratory and Critical Care Medicine, 159, 179–187.
Harrell, F. E. (2007). Harrell miscellaneous. Retrieved Jan 16, 2008, from http://biostat.mc.vanderbilt.edu/s/Hmisc.
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10, 407–415.
Juniper, E. F., Guyatt, G. H., Feeny, D. H., Ferrie, P. J., Griffith, L. E., & Townsend, M. (1996). Measuring quality of life in children with asthma. Quality of Life Research, 5, 35–46.
Kolotkin, R. L., & Crosby, R. D. (2002). Psychometric evaluation of the Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-lite) in a community sample. Quality of Life Research, 11, 157–171.
Kosorok, M. R., Wei, W. H., & Farrell, P. M. (1996). The incidence of cystic fibrosis. Statistics in Medicine, 15, 449–462.
Landgraf, J., Abetz, L., & Ware, J. E. (1996). Child Health Questionnaire (CHQ): A user’s manual. Boston: The Health Institute, New England Medical Center.
Le Pen, C., Levy, E., Loos, F., Banzet, M. N., & Basdevant, A. (1998). “Specific” scale compared with “generic” scale: A double measurement of the quality of life in a French community sample of obese subjects. Journal of Epidemiology and Community Health, 52, 445–450.
Liou, T. G., Adler, F. R., Fitzsimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001). Predictive 5-year survivorship model of cystic fibrosis. American Journal of Epidemiology, 153, 345–352.
Modi, A. C., & Quittner, A. L. (2003). Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. Journal of Pediatric Psychology, 28, 535–545.
Munzenberger, P. J., Van Wagnen, C. A., Abdulhamid, I., & Walker, P. C. (1999). Quality of life as a treatment outcome in patients with cystic fibrosis. Pharmacotherapy, 19, 393–398.
Orenstein, D. M., Pattishall, E. N., Nixon, P. A., Ross, E. A., & Kaplan, R. M. (1990). Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest, 98, 1081–1084.
Palermo, T. M., Harrison, D., & Koh, J. L. (2006). Effect of disease-related pain on the health-related quality of life of children and adolescents with cystic fibrosis. Clinical Journal of Pain, 22, 532–537.
Quittner, A. L., Buu, A., Messer, M. A., Modi, A. C., & Watrous, M. (2005). Development and validation of the Cystic Fibrosis Questionnaire (CFQ) in the United States: A health-related quality of life measure for cystic fibrosis. Chest, 128, 2347–2354.
Quittner, A. L., McCoy, J. K., & Montgomery, A. B. (2007). Inhaled antibiotics to treat stable patients with cystic fibrosis and Pseudomonas aeruginosa (PA): Measuring patient perception of symptom improvement. Pediatric Pulmonology, S30, 280.
Quittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009). Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest, 135, 1610–1618.
Quittner, A. L., Modi, A. C., Watrous, M., Davis, M. A. (2003). The Cystic Fibrosis Questionnaire Revised (CFQ-R): User’s manual. Washington, DC: Cystic Fibrosis Foundation.
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., et al. (1999). Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. New England Journal of Medicine, 340, 23–30.
Rosenfeld, M. (2005). Overview of published evidence on outcomes with early diagnosis from large US observational studies. Journal of Pediatrics, 147, S11–S14.
Schipper, H., Clinch, J. L., & Olweny, L. M. (1996). Quality of life studies: Definitions and conceptual issues. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed., pp. 11–24). Philadelphia: Lippincott-Raven.
U.S Food and Drug Administration. (2006). Guidance for industry patient reported outcome measures: Use in medical product development to support labeling claims (Draft Guidance).
Varni, J. W., Seid, M., & Kurtin, P. S. (2001). PedsQL 4.0: Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical Care, 39, 800–812.
Wang, X., Dockery, D. W., Wypij, D., Fay, M. E., & Ferris, B. G., Jr. (1993). Pulmonary function between 6 and 18 years of age. Pediatric Pulmonology, 15, 75–88.
Wolter, J. M., Bowler, S. D., Nolan, P. J., & McCormack, J. G. (1997). Home intravenous therapy in cystic fibrosis: A prospective randomized trial examining clinical, quality of life and cost aspects. European Respiratory Journal, 10, 896–900.
Yi, M. S., Tsevat, J., Wilmott, R. W., Kotagal, U. R., & Britto, M. T. (2004). The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: Does hospitalization make a difference? Journal of Pediatrics, 144, 711–718.
Acknowledgements
We would like to extend our deepest appreciation to the children, adolescents and caregivers who participated in this study. We would also like to thank the research assistants and summer students who were instrumental in recruiting participants and collecting data, including Julie Koumoutsos, Sarah Valentine, Neha Godiwala, Matt Flanigan, and Stephanie Sullivan. We would also like to thank the CF Teams at the University of Florida and Cincinnati Children’s Hospital Medical Center for their support.
Funding/Support
This study was supported by a post-doctoral training grant from the National Institutes of Health (T32 DK063929) to the first, third, and fourth author.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Modi, A.C., Lim, C.S., Driscoll, K.A. et al. Changes in Pediatric Health-Related Quality of Life in Cystic Fibrosis After IV Antibiotic Treatment for Pulmonary Exacerbations. J Clin Psychol Med Settings 17, 49–55 (2010). https://doi.org/10.1007/s10880-009-9179-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10880-009-9179-2